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BACKGROUND: Non-steroidal anti-inflammatory drug (NSAID) use has been linked with pancreatic cancer risk; however, findings
from epidemiological studies are inconsistent.
METHODS: A nested case–control study was conducted within the UK General Practice Research Database. Cases (n¼1141) had a
diagnosis of primary cancer of the exocrine pancreas between January 1995 and June 2006. Controls (n¼7954) were matched
with each case on general practice site, sex and year of birth. Conditional logistic regression analyses were used to generate odds
ratios (OR) and 95% confidence intervals (CI) associated with NSAID use compared with non-use.
RESULTS: Any use of NSAID in the 5 years before the index date or since entry into the database (excluding the year before diagnosis)
was not associated with risk of pancreatic cancer; OR 0.96 (95% CI, 0.84–1.10) and 1.03 (95% CI 0.89–1.19), respectively.
Exposure to NSAIDs for 4 773 days, in the 5 years pre-diagnosis, was associated with a reduced risk of pancreatic cancer OR
0.78 (95%CI 0.62–0.97). There was evidence of reduced pancreatic cancer risk with long-term use (5 years or more) of lower doses
of NSAIDs OR 0.70 (95% CI 0.49–0.99).
CONCLUSION: Long-term exposure to NSAIDs may be associated with a reduction in risk of pancreatic cancer.
British Journal of Cancer (2010) 102, 1415–1421. doi:10.1038/sj.bjc.6605636 www.bjcancer.com
Published online 6 April 2010
& 2010 Cancer Research UK
Keywords: NSAIDs; aspirin; pancreatic cancer; GPRD
                                                 
Pancreatic cancer is rapidly fatal and is the fifth leading cause
of cancer mortality in the western world. (Jemal et al, 2007) It is
therefore important to identify aetiological and protective factors
for this disease to improve primary prevention. Non-steroidal
anti-inflammatory drugs (NSAIDs), especially aspirin, have been
reported to reduce the risk of several cancers and some
pre-malignant lesions, with risk reductions ranging from 20% to
50% for certain cancer sites (Garcia-Rodriguez and Huerta-
Alvarez, 2001; Khuder and Mutgi, 2001; Gonzalez-Perez et al,
2003; Abnet et al, 2009; Cole et al, 2009).
However, despite biologically plausible mechanisms whereby
NSAIDs may prevent pancreatic cancer, the findings of epidemio-
logic studies are inconsistent (Schreinmachers and Everson,
1994; Coogan et al, 2000; Langman et al, 2000; Anderson et al,
2002a; Menezes et al, 2002; Friis et al, 2003; Sorensen et al, 2003;
Jacobs et al, 2004; Ratnasinghe et al, 2004; Schernhammer et al,
2004; Cook et al, 2005). In a recent meta-analysis of these studies,
the combined relative risk of pancreatic cancer in regular users of
NSAIDs compared with non-regular or never users was 1.01 (95%
confidence intervals (CI) 0.91–1.11) (Larsson et al, 2006). The
Women’s Health Study randomised controlled trial reported
similar null findings (Cook et al, 2005). The inconsistency between
laboratory and epidemiological evidence prompted us to examine
the association between NSAIDs and pancreatic cancer risk in the
UK General Practice Research Database (GPRD), particularly
because most studies have been undertaken within the US,
(Capurso et al, 2007) where NSAIDs are used at higher doses
and for longer durations than in the UK (Arellano et al, 2006).
MATERIALS AND METHODS
We undertook a nested case–control study within the UK GPRD,
which was established in 1987, and is the world’s largest
computerised database of anonymised longitudinal patient records
from primary care. It collects data from around 500 general
practices in the UK, covers about 5.5% of the population and is
broadly representative of the UK population (GPRD, 2009).
Participating practices follow protocols for the recording and trans-
ferring of computerised data to the research database (Hollowell,
1997). The data obtained are assessed in terms of completeness,
continuity and plausibility and are from general practices that meet
predefined standards, registered as ‘up to standard’ (UTS) practices.
GPRD data includes demographic information, clinical diagnoses,
referral information, specialty consultation notes, results of
laboratory tests and hospital discharge information. Read and
Oxford Medical Information System (OXMIS) codes are used to
classify medical diagnoses. The GPRD also contains details of all
prescriptions issued for registered patients (Garcia Rodriguez and
Perez Gutthann, 1998). The high quality of GPRD prescription
and diagnosis information has been documented (Jick et al, 1991;
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for all observational research using GPRD data has been obtained
from a Multicentre Research Ethics Committee.
The study included patients from UTS practices with diagnostic
codes for primary pancreatic cancer, with a date of diagnosis/index
date (first recorded occurrence of a pancreatic cancer code)
between January 1995 and June 2006; data were extracted from
GPRD in February 2007. Patients aged 85 or older were excluded,
as were cases without at least 5 years of UTS data collection before
the index date. Controls with no GPRD record of pancreatic cancer
were selected using incidence density sampling and matched to
cases on year of birth, sex and general practice site. Controls also
had at least 5 years of UTS data collection before their index date
(date of pancreatic cancer diagnosis in their matched case). Up to
seven controls were matched for each case.
Pancreatic cancer is difficult to conclusively diagnose without
histological or cytological examination of relevant specimens and
these specimens are often not available. Pancreatic cancer may
therefore be confused with primary malignancies in adjacent
organs or with secondary tumours. Histological confirmation was
not available from GPRD as there was no routine linkage to cancer
registries, at the time the data were obtained. To minimise
misclassification, all cancer codes recorded in the medical records
of potential cases were reviewed. Only cases with consistently
recorded pancreatic cancer codes were included. All other cases,
for example patients with codes for both pancreatic cancer and
cholangiocarcinoma, or carcinoma of bile duct, gallbladder and so
on, and their matched controls were excluded from the dataset;
peri-ampullary tumours were also excluded. Cases and controls
with a prior history of cancer (at least a year before the index date)
were identified by review of cancer codes and flagged as having a
previous cancer but were not excluded from the dataset.
The primary exposure of interest was NSAID use in the 5 years
before the index date, excluding t h ey e a rb e f o r et h ei n d e xd a t e .
NSAID use in the year before diagnosis was excluded because early
cancer symptoms may have led to NSAID use during this period.
NSAID use since entry into GPRD until a year before the index date
was also examined. Data were extracted on all NSAIDs prescribed for
cases and controls. NSAID use was expressed in units of defined daily
dose (DDD), a validated measure of drug consumption maintained
by the World Health Organisation (WHO). It is the assumed average
maintenance dose per day of a drug used for its main indication in
adults. (World Health Organisation Working Group, 2008) As the
DDD of a drug may be assumed to be functionally equivalent to the
DDD of any other drug used for a similar purpose, DDDs may be
used to compare or combine the usage of drugs within and across
pharmacological groups, for example all NSAIDs.
The number of DDDs for each NSAID prescription issued
was calculated by multiplying the dose prescribed by the quantity
given and dividing this by the DDD value assigned to that drug.
For each time period under study, the total number of DDDs for
each NSAID prescribed, for subgroups of NSAIDs (aspirin and
derivatives, high-dose aspirin (300mg or more a day), fenamates,
propionic acid derivatives, acetic acid derivatives, COX-2 inhibi-
tors, oxicams or others), and for all NSAIDS combined was
calculated for each case and control. Cumulative duration of any
NSAID use was calculated as the total number of intended days,
during the periods under study, for which study subjects were
issued any prescription (at any dose) for NSAIDs. Total dose
(DDDs) and total duration (days) of any NSAID use, in the periods
under study, were categorised into approximate quartiles, on the
basis of total NSAID use within the controls.
Exposure to any NSAID at any time before the index date,
excluding the year before the index date, was further categorised
according to both dose and duration of use combined. The median
number of DDDs, per day, of NSAID exposure in the controls
during this period was one DDD per day, therefore low-dose
NSAID exposure was classified as the use of o1.0 DDD of NSAIDs
per day and high dose as 41.0 DDDs per day. Categories
for duration of low and high NSAID use were subsequently
created: no use or use for o1 year (0–365.3 days), use for 1–3
years (365.3–1095.8 days), use for 3–5 years (1095.8–1826.3 days)
and use for 5 or more years (41826.3) (Yang et al, 2007).
Statistical analysis
Conditional logistic regression was used to calculate odds ratios
(ORs) and 95% percent CIs for the associations between disease
status and use of NSAIDs.
Models were constructed for ever/never use of all NSAIDs
or subgroups of NSAIDs. Dose and duration of NSAID use was
examined using continuous variables (output expressed per 200
DDDs and 200 days of use), approximate quartiles of dose and
duration of NSAID use and the combined dose and duration
variable. NSAID use in the year before diagnosis was excluded in
all analyses and models were constructed relating to the 5-year
period before diagnosis/index date and since entry into the GPRD.
All analyses were adjusted for potential confounders including
smoking status (unknown, current smoker, non-smoker,
ex-smoker), body mass index (BMI, unknown, underweight,
normal, overweight, obese according to WHO categories) (World
Health Organisation Working Group, 2009), alcohol use (un-
known, current drinker, lifelong non-drinker, ex-drinker), history
of pancreatitis, history of rheumatoid arthritis, history of diabetes
and history of cancer. For smoking, alcohol use and BMI, we used
the most recent record excluding those within the year before the
index date and for history of diabetes, pancreatitis and cancer we
also excluded events within the year before the index date. We also
adjusted for use of H2 antagonists (ever/never use) or proton pump
inhibitors (PPIs, ever/never use), systemic steroids (ever/never use),
hormone replacement therapy (HRT, ever/never use) and disease
modifying anti-rheumatic drugs as use of these drugs may confound
the association between NSAIDs and pancreatic cancer. Use of HRT
and steroids in the year before diagnosis was excluded. As there was
a strong positive association between use of H2 antagonists and
PPIs in the 2 years before diagnosis (presumably because of cancer-
associated symptoms) use of these drugs within this period was
excluded. Data on the confounders were not available for all
subjects and for those subjects for whom all data was available, a
restriction analyses was carried out. STATA Version 9 (Timberlake
Consultants Ltd, London, UK) was used for all analyses.
RESULTS
Within the GPRD, 1361 pancreatic cancer cases met the initial
inclusion criteria and these were matched to 9487 controls. After
review of cancer codes, 220 cases (16%) and their controls (1542,
9.4%) were excluded, leaving 1141 pancreatic cancer cases and
7954 matched controls. Each case had at least one matched control
and 490% of cases had seven matched controls. The mean
duration of UTS follow-up was 10.6 (s.d. 3.4) years, for both
cases and controls. The mean age at database enrolment was also
the same for cases and controls at 57.3 (s.d. 9.8) years; over 50%
(53.7%) of all subjects were male (Table 1).
Any use of an NSAID in the 5 years before the index date or
since entry into the GPRD (excluding the year before diagnosis)
was not associated with risk of pancreatic cancer; (OR) 95% CI,
0.96 (0.84–1.10) and 1.03(0.89–1.19), respectively (Data not
shown). Any use of aspirin and its derivatives or high-dose aspirin
in the 5 years before the index date was also not associated with
pancreatic cancer risk: ORs (95% CI), 0.95 (0.81–1.13) and 0.91
(0.61–1.35), respectively, and similar results were seen when use
since entry into the GPRD was examined (Table 2). Among
subgroups of NSAIDs, risk of pancreatic cancer was lowest among
users of COX-2 inhibitors and oxicams but the reductions in risk
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(0.56–1.11) and 0.67 (0.43–1.03), respectively for use in the 5 years
before diagnosis. Use of other subgroups of NSAIDs (acetic acid
derivatives, fenamates, propionic acid derivatives or other
NSAIDs) was not associated with pancreatic cancer risk (Table 2).
There was also no overall association between pancreatic cancer
risk and the total dose of NSAIDs used in the 5 years before the
index date or since entry into the GPRD (excluding the year before
diagnosis). The adjusted ORs (95% CI) for an increase in 200
DDDs of NSAIDs in these two periods were 0.99 (0.94–1.03) and
0.99 (0.97–1.01), respectively (Data not shown). When the dose of
NSAIDs was categorised according to use in controls (approximate
quartiles) no association was seen between dose category and
pancreatic cancer risk (Table 3).
Table 1 Characteristics of cases and controls
Cases
(n¼1141)
Controls
(n¼7954)
P
value
Age at database enrolment
(years, s.d.)
57.3 (9.8) 57.3 (9.8) 1.0
Male sex (%) 53.7 53.7 1.0
Mean duration of follow-up
before index date (years, s.d.))
10.6 (3.4) 10.6 (3.4) 1.0
Smoking status o0.005
Current smoker 302 (26.5%) 1372 (17.3%)
Non-smoker 463 (40.6%) 3961 (49.8%)
Ex-smoker 235 (20.6%) 1499 (18.9%)
Missing data 141 (12.4%) 1122 (14.1%)
Body mass index (kgm
 2) 0.1
o18.5 16 (1.4%) 102 (1.3%)
X18.5 & o25 353 (31.0%) 2323 (29.2%)
X25 & o30 343 (30.1%) 2525 (31.8%)
X30 187 (16.4%) 1108 (13.9%)
Missing 242 (21.2%) 1896 (23.8%)
Current drinking status 0.4
Current drinker 731 (64.1%) 4992 (62.8%)
Non-drinker 165 (14.5%) 1107 (13.9%)
Ex-drinker 7 (0.6%) 77 (1.0%)
Missing data 238 (20.9%) 1778 (22.4%)
Hormone replacement therapy use 0.3
Never 1095 (95.9%) 7574 (95.2%)
Ever 46 (4.1%) 380 (4.8%)
Steroid use 0.2
Never 990 (86.8%) 6999 (88.0%)
Ever 151 (13.2%) 955 (12.0%)
Pancreatitis o0.005
Never 1085 (95.1%) 7901 (99.3%)
Ever 56 (4.9%) 53 (0.7%)
Proton pump inhibitor use 0.3
Never 964 (84.5%) 6817 (85.7%)
Ever 177 (15.5%) 1137 (14.3%)
H2 antagonist use o0.005
Never 877 (76.9%) 6423(80.8%)
Ever 264 (23.1%) 1531 (19.2%)
Diabetes o0.005
Never 1006 (88.2%) 7442 (93.5%)
Ever 135 (11.8%) 512 (6.4%)
Prior cancer 0.4
Never 1049 (91.9%) 7374 (92.7%)
Ever 92 (8.1%) 580 (7.3%)
Rheumatoid arthritis
RA codes 0.2
Never 1131 8993
Ever 10 102
Disease modifying anti-rheumatic drugs prescription 0.9
Never 1126 8993
Ever 15 102
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and duration of NSAID use in the 5 years before the index date.
NSAID use for 773 days or more (approximately 2 years) in this
period (excluding the year before the index date) was associated
with a decrease in risk; adjusted ORs (95% CI), 0.78 (0.62–0.97)
(Table 4). No association was seen in the period since entry into
the GPRD (Table 4). Results of the analysis that combined dose
and duration of NSAID use since entry into GPRD (excluding the
year before the index date) are shown in Table 5. There was
also some evidence in this analysis of reduced pancreatic cancer
risk with long-term use (use for 1826.3 days or more) of lower
doses of NSAIDs (o1 DDD a day); adjusted ORs (95% CI), 0.70
(0.49–0.99).
DISCUSSION
In this large population-based prospective study no significant
reductions in risk of pancreatic cancer were seen for ever
compared with never use of an NSAID. There was also no overall
association between risk and the total dose prescribed and no risk
reduction was seen among subjects who used the highest doses of
NSAIDs. A 20% reduction in risk was seen among subjects who
had been prescribed an NSAID for approximately 2 years or longer
in the 5 years before diagnosis and a 30% reduction in subjects
who had used lower than average doses of NSAIDs for 5 years
(1826.3 days) or more since entry into the GPRD. However,
no consistent pattern of reduced risk was seen with increasing
dose, duration or combined dose and duration of NSAID use.
Modest reductions in long-term users of higher doses of
NSAIDs were seen but were not statistically significant. Although
chance and residual confounding may explain the latter findings,
these data suggest that long-term use (42 years) of NSAIDs
(at regular anti-inflammatory doses) may protect against pancrea-
tic cancer and that duration of use may be more important
than dose.
Two recent meta-analyses found no association between aspirin/
NSAID use and pancreatic cancer. (Larsson et al, 2006; Capurso
et al, 2007). Capurso et al (2007) reported pooled ORs (95% CI) for
pancreatic cancer risk of 0.99 (0.83–1.19), 1.11 (0.84–1.47) and
1.09 (0.67–1.75) in low, intermediate and high aspirin/NSAID
exposure groups, respectively (based on a combination of dose and
duration). Duration of use was not examined separately from dose
in this meta-analysis. A previous study using the GPRD, which
included fewer pancreatic cancer cases (513) than our study,
reported an OR of 1.49 (1.02–2.18) for patients receiving 7 or more
prescriptions for NSAIDs in the 13–36 months before the
diagnosis date of the case (Langman et al, 2000). This study may
have comprised cases also included in our analysis, but we believe
our study was more rigorous as it examined both the dose
and duration of NSAID exposure rather than the number of
NSAID prescriptions issued; similarly, the UTS follow-up time
(a minimum of 5 years) and the median follow-up time (10.6 years)
in our study were longer than in the earlier study (at least 3 years).
Moreover, the risk estimates reported in that study were adjusted
only for age and smoking status, whereas we applied a
comprehensive range of adjustments.
Ever use of aspirin was not associated with pancreatic cancer
risk in our study, which is not unexpected as the majority of
aspirin users (83%) used low-dose aspirin only (o300mg) and
data from cohort studies (Friis et al, 2003) and large trials have not
shown any decrease in pancreatic cancer risk in users of low-dose
aspirin (Cook et al, 2005). Use of greater than five aspirin tablets
per week (high dose, 325mg) for 10 years or more in the Nurses’
Health Study was associated with an increased the risk of
pancreatic cancer compared with those who used aspirin for 1–5
years (Schernhammer et al, 2004). Data from the two large
randomised trials, with reliable post trial follow-up for more than
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y20 years, also suggested that high-dose aspirin may increase the
risk of pancreatic cancer slightly (Flossmann et al, 2007). We did
not see any increase in risk in subjects using high-dose aspirin but
we were unable to assess risk in long-term users of high-dose
aspirin as only 17% used this dose at any time.
Ever versus never use of COX-2 inhibitors and oxicams
was associated with modest reductions in pancreatic cancer risk
(20% and 30%, respectively) but statistical significance was not
achieved and too few subjects took these preparations to allow a
more detailed analysis of use of these drugs. Trials of COX-2
inhibitors in patients with colorectal adenomas or previous
colorectal cancer have shown that these drugs can successfully
prevent colorectal carcinogenesis (Arber et al, 2006; Baron et al,
2006; Bertagnolli et al, 2006) but adverse effects on cardiovascular
risk mean that they are also unlikely to be of benefit for the
prevention of cancer, especially if a high-risk pre-malignant state
is not clearly recognised (Lynch, 2006). Meloxicam has been
described as a preferential COX-2 inhibitor and as with piroxicam
has shown inhibitory actions on human cancers (Ding et al, 2003;
Naruse et al, 2006). This is the first study to report on the use of
oxicams and pancreatic cancer prevention and further analysis is
warranted.
This analysis has several key strengths, being the largest and
most detailed of the subject to date, allowing us to stratify the
analyses by dose, duration and subgroup of NSAID. The use of
prospectively collected prescription data avoids errors of recall and
potential recall bias associated with questionnaire-based measures
of NSAID use. Moreover, all subjects in our study had at least
5 years of data available before diagnosis and data were available
before diagnosis for a mean of over 10 years. We also adjusted for
all major confounders and, although data were not available for all
subjects, the results of restriction analyses including only those
patients who had data on these confounders were not different
from the main analyses. However, we cannot rule out residual
confounding. We do not believe that confounding by indication is
a major problem within the study as indications for which NSAIDs
are used are very varied and it is unlikely that each indication
would have a common association with pancreatic cancer risk. We
attempted to address such confounding by adjusting for a history
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Table 5 Pancreatic cancer risk according to dose and duration of non-
steroidal anti-inflammatory drugs (NSAID) use since entry into General
Practice Research Database (excluding the year before the index date)
Dose of NSAID
Low dose (o1.0 DDD per day)
Duration of
NSAID use (days)
Cases
(n)
Controls
(n)
OR
(95% CI)
Adjusted
OR(95%CI)
a
Non-user and use
for 0–365.3
504 3560 1.0 1.0
365.3–1095.8 87 518 1.33 (1.02–1.74) 1.17 (0.88–1.56)
1095.8–1826.3 48 355 1.02 (0.73–1.43) 0.95 (0.66–1.34)
1826.3 or more 48 421 0.79 (0.56–1.11) 0.70 (0.49–0.99)
High dose (X1.0DDD per day)
Non-user and use
for 0–365.3
705 4976 1.0 1.0
365.3–1095.8 52 332 1.11 (0.81–1.52) 1.02 (0.73–1.42)
1095.8–1826.3 18 180 0.69 (0.42–1.14) 0.67 (0.39–1.12)
1826.3 or more 24 177 0.89 (0.56–1.40) 0.85 (0.53–1.36)
Abbreviation: DDD¼defined daily dose.
aAdjusted for smoking status, body mass
index, alcohol use, history of chronic pancreatitis, history of rheumatoid arthritis, use
of other drugs (proton pump inhibitors, H2 antagonists, steroids, hormone
replacement therapy and disease modifying anti-rheumatic drugs), diabetes and
prior cancer.
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yof rheumatoid arthritis, a common indication of chronic NSAID
use; it made no difference to observed ORs.
This study has some limitations. Data on prescriptions issued
may not reflect actual use of NSAIDs but there is no reason to
believe that non-compliance with prescription medication would
differ systematically between cases and controls. No information
was available on over-the-counter (OTC) NSAID use (including
that from non-pharmacy outlets) but there is little evidence of
large-scale OTC purchasing of NSAIDs in the UK, especially
in the middle aged and elderly. (Meier et al, 2002) Pancreatic
cancer diagnoses were not validated and some misclassification of
diagnoses may have occurred within the GPRD system but we
excluded very elderly subjects, in which diagnostic accuracy may
be a particular problem; also, all cancer codes were reviewed and
cases with inconsistent coding were excluded. Furthermore, cancer
diagnoses in GPRD appear to be a reliable record of incident
cancer diagnoses and have been shown to concord with original
medical records in 95% of cases. (Jick et al, 1997)
In summary, this study suggests that long-term use (42 years)
of NSAIDs may protect against pancreatic cancer but replication of
these findings is required.
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